연구진 소개

I am a surgeon who primarily performs surgical treatment for colon and rectal cancer. For surgical treatment, I mainly perform minimally invasive surgery, including laparoscopic and robotic surgery, and I am conducting related research. In particular, I have a strong interest in the treatment of rectal cancer, which is associated with a high rate of postoperative sequelae and a high incidence of locoregional recurrence. For rectal cancer, the recent active adoption of neoadjuvant (preoperative) treatment has led to an increasing number of cases achieving complete response without the need for surgical treatment, and I am highly interested in patient selection, treatment, and early diagnosis of recurrence in this context. In terms of preclinical research, I am highly interested in establishing ex vivo cancer models from surgical specimens, and I am currently culturing colorectal cancer patient-derived organoids (PDOs), with plans to establish patient-derived xenograft (PDX) models in the future.

Professor Park's primary research interests include precision medicine for colorectal cancer, minimally invasive and robotic surgery, and translational research. In particular, he conduct studies integrating diverse multi-omics data, including patient-derived organoids, the microbiome, cancer genomics, transcriptomics, proteomics, and metabolomics, to predict responses to neoadjuvant chemoradiotherapy and total neoadjuvant therapy in rectal cancer. Through these efforts, he aims to identify predictive biomarkers of treatment response and develop personalized therapeutic strategies for individual patients. He is also interested in developing prognostic models, postoperative complication prediction models, and clinical decision-support tools for patients with colorectal cancer by leveraging medical artificial intelligence, healthcare big data, and real-world data. Based on clinical trials and prospective cohort studies, his research seeks to generate clinically applicable evidence and integrate it with precision medicine and digital healthcare. Ultimately, his research focuses on improving treatment outcomes for patients with colon and rectal cancer and establishing a personalized cancer care platform that integrates surgery, systemic therapy, molecular diagnostics, and artificial intelligence.